Reaction
Onychalgia reporting signals
As of the last recalculation, Onychalgia appears in 988 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is LAPATINIB (PRR 47.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Lapatinib | 34 | 47.8 | 47.9 |
| Granisetron Hydrochloride | 12 | 24.5 | 24.5 |
| Granisetron | 12 | 24.4 | 24.4 |
| Trastuzumab | 73 | 24.1 | 24.1 |
| Pertuzumab | 25 | 19.9 | 19.9 |
| Osimertinib | 28 | 18.9 | 18.9 |
| Ado-Trastuzumab Emtansine | 7 | 17.6 | 17.6 |
| Erlotinib | 8 | 17.5 | 17.5 |
| Terbinafine Hydrochloride | 7 | 16.7 | 16.7 |
| Erlotinib Hydrochloride | 9 | 15.3 | 15.3 |
| Panitumumab | 9 | 12.2 | 12.2 |
| Aprepitant | 10 | 11.5 | 11.5 |
| Abemaciclib | 10 | 10.6 | 10.6 |
| Docetaxel Anhydrous | 31 | 10.0 | 10.0 |
| Docetaxel | 31 | 10.0 | 10.0 |
| Capecitabine | 40 | 9.6 | 9.6 |
| Cortisone Acetate | 5 | 8.6 | 8.6 |
| Cabozantinib | 19 | 8.5 | 8.5 |
| Cetuximab | 11 | 7.5 | 7.5 |
| Ixekizumab | 9 | 5.2 | 5.2 |